Estrogen therapy and thrombotic risk

Pharmacology and Therapeutics

Volumn 111, Issue 3, 2006, Pages 792-807

  Miller, Virginia M ^a   Jayachandran, Muthuvel ^a   Heit, John A ^a   Owen, Whyte G ^a,b  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

17 estradiol; C reactive protein; KEEPS trial; Platelets; Venous thrombosis; Women's Health Initiative

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; INDOMETACIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; N(G) METHYLARGININE; PLACEBO; PROGESTERONE; PROSTAGLANDIN SYNTHASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR NECROSIS FACTOR;

AGE DISTRIBUTION; ARTERIOSCLEROSIS; ARTERY DISEASE; ARTERY THROMBOSIS; BLOOD CLOTTING; BLOOD VESSEL WALL; CEREBROVASCULAR ACCIDENT; CHOLESTEROL DIET; CLINICAL TRIAL; DISEASE COURSE; DNA POLYMORPHISM; ESTROGEN THERAPY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HEART INFARCTION; HUMAN; LEUKOCYTE; MENOPAUSAL SYNDROME; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; THROMBOCYTE; THROMBOSIS; TRANSGENE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ARTERIES; BLOOD PLATELETS; C-REACTIVE PROTEIN; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENOTYPE; HUMANS; LEUKOCYTES; RECEPTORS, ESTROGEN; RISK FACTORS; THROMBOSIS; VEINS;

EID: 33746363509     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2006.01.001     Document Type: Review

References (196)

1. Aavik E., du Toit D., Myburgh E., Frosen J., and Hayry P. Estrogen receptor beta dominates in baboon carotid after endothelial denudation injury. Mol Cell Endocrinol 182 (2001) 91-98
2. Akhrass F., Evans A.T., Wang Y., Rich S., Kannan C.R., Fogelfeld L., et al. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 88 (2003) 5611-5614
3. Alexander C., and Rietschel E.T. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 7 (2001) 167-202
4. American Heart Association. Heart Disease and Stroke Statistics-2003 Update (2002), American Heart Association, Dallas, TX
5. Ameziane N., Beillat T., Verpillat P., Chollet-Martin S., Aumont M.-C., Seknadji P., et al. Association of the toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 23 (2003) e61-e64
6. Andonegui, G., Kerfoot, S. M., McNagny, K., Ebbert, K. V. J., Patel, K. D., Kubes, P. (2005). Platelets express functional toll-like receptor-4 (TLR4). Blood June 16, 2005; DOI 10.1182/blood-2005-03-0916.
7. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25 (2000) 187-191
8. Ariens R.A., de Lange M., Snieder H., Boothby M., Spector T., and Grant P. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 359 (2002) 667-671
9. Bar J., Tepper R., Fuchs J., Pardo Y., Goldberger S., and Ovadia J. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 81 (1993) 261-264
10. Bar J., Lahav J., Hod M., Ben-Rafael Z., Weinberger I., and Brosens J. Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17b-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb Haemost 84 (2000) 695-700
11. Barrett-Connor E., and Bush T.L. Estrogen and coronary heart disease in women. J Am Med Assoc 265 (1991) 1861-1867
12. Best P.J.M., Lerman L.O., Romero J.C., Richardson D., Holmes Jr. D.R., and Lerman A. Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro. Arterioscler Thromb Vasc Biol 19 (1999) 2769-2775
13. Bombeli T., Piccapietra B., Boersma J., and Fehr J. Decreased anticoagulant response to tissue factor pathway inhibitor in patients with venous thromboembolism and otherwise no evidence of hereditary or acquired thrombophilia. Thromb Haemost 91 (2004) 80-86
14. Bouchard B.A., and Tracy P.B. Platelets, leukocytes, and coagulation. Curr Opin Hematol 8 (2001) 263-269
15. Boudoulas K.D., Cooke G.E., Roos C.M., Bray P.F., and Goldschmidt-Clermont P.J. The PIA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 125 (2001) 112-115
16. Bovill E., Bauer K., Dickerman J., Callas P., and West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 73 (1989) 712-717
17. Bracamonte M.P., Jayachandran M., Rud K.S., and Miller V.M. Acute effects of 17b-estradiol on femoral veins from adult, gonadally intact and ovariectomized female pigs. Am J Physiol:Heart Circ Physiol 283 (2002) H2389-H2396
18. Bracamonte M.P., Rud K.S., and Miller V.M. Mechanism of raloxifene-induced relaxation in femoral veins depends on ovarian hormonal status. J Cardiovasc Pharmacol 39 (2002) 704-713
19. Bracamonte M.P., Rud K.S., Owen W.G., and Miller V.M. Ovariectomy increases mitogens and platelet-induced proliferation of arterial smooth muscle. Am J Physiol Heart Circ Physiol 283 (2002) H853-H860
20. Broze Jr. G.J. Human protein Z. J Clin Invest 73 (1984) 933-938
21. Cale A.R.J., Ricagna F., Wiklund L., McGregor C.G.A., and Miller V.M. Mononuclear cells from dogs with acute lung allograft rejection cause contraction of pulmonary arteries. Circulation 90 (1994) 952-958
22. Catto A.J., Kohler H.P., Coore J., Mansfield M.W., Strickland M.H., and Grant P.J. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 93 (1999) 906-908
23. Chambliss K.L., and Shaul P.W. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 23 (2002) 665-686
24. Chambliss K.L., Yuhanna I.S., Mineo C., Liu P.S., German Z., Sherman T.S., et al. Estrogen receptor a and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res 87 (2000) E44-E52
25. Chan C.-C., and Kalsner S. Termination of responses to sympathetic nerve stimulation and to noradrenaline in a perfused arterial preparation: the role of neuronal and extraneuronal uptake. J Pharmacol Exper Ther 222 (1982) 731-740
26. Chen S.-J., Li H., Durand J., Oparil S., and Chen Y.-F. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 93 (1996) 577-584
27. Chen Z., Yuhanna I.S., Galcheva-Gargova Z., Karas R.H., Mendelsohn M.E., and Shaul P.W. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 103 (1999) 401-406
28. Chung H.J., Champagne C.M.E., Southerland J.H., Geva S., Liu Y., Paquette D.W., et al. Effects of P. gingivalis infection on atheroma formation in ApoE(-) mice. J Dent Res 79 (2000) 313 Spec. Issue, Abstr. 1358
29. Claus D.R., Osmand A.P., and Gewurz H. Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med 87 (1976) 120-128
30. Cognasse F., Hamzeh H., Chavarin P., Acquart S., Genin C., and Garraud O. Evidence of toll-like receptor molecules on human platelets. Immunol Cell Biol 83 (2005) 196-198
31. Comp P.C., and Esmon C. Recurrent venous thromboembolism in patients with partial deficiency of protein S. N Engl J Med 311 (1984) 1525-1528
32. Cosman F., Baz-Hecht M., Cushman M., Vardy M.D., Cruz J.D., Nieves J.W., et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 116 (2005) 1-13
33. Cushman M., Legault C., Barrett-Connor E., Stefanick M.L., Kessler C., Judd H., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100 (1999) 717-722
34. Cushman M., Meilahn E.N., Psaty B.M., Kuller L.H., Dobs A.S., and Tracy R.P. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 19 (1999) 893-899
35. Darblade B., Pendaries C., Krust A., Dupont S., Fouque M.-J., Rami J., et al. Estradiol alters nitric oxide production in the mouse aorta through the α-, but not β-, estrogen receptor. Circ Res 90 (2002) 413-419
36. Day S.M., Reeve J.L., Myers D.D., and Fay W.P. Murine thrombosis models. Thromb Haemost 92 (2004) 486-494
37. de Lange M., Snieder H., Ariens R.A., Spector T.D., and Grant P.J. The genetics of haemostasis: a twin study. Lancet 357 (2001) 101-105
38. Decensi A., Omodei U., Robertson C., Bonanni B., Guerrieri-Gonzaga A., Ramazzotto F., et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 106 (2002) 1224-1228
39. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13 (1965) 516-530
40. Engstrom G., Stavenow L., Hedblad B., Lind P., Tyden P., Janzon L., et al. Inflammation-sensitive plasma proteins and incidence of myocardial infarction in men with low cardiovascular risk. Arterioscler Thromb Vasc Biol 23 (2003) 2247-2251
41. Esmon C.T. Coagulation and inflammation. J Endotoxin Res 9 (2003) 192-198
42. Fong I.W. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. Can Med Assn J 163 (2000) 49-56
43. Frank M.W., Mehlman D.J., Tsai F., Lomasney J.W., and Joob A.W. Syphilitic aortitis. Circulation 100 (1999) 1582-1583
44. Frishman W.H., and Ismail A. Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target?. Cardiol Rev 10 (2002) 199-210
45. Garcia-Duran M., deFrutos T., Diaz-Recasens J., Garcia-Galvez G., Jimenez A., Monton M., et al. Estrogen stimulates neuronal nitric oxide synthase protein expression in human neutrophils. Circ Res 85 (1999) 1020-1026
46. Gerhard M.D., Tawakol A., Haley E.A., Creager S.J., Walsh B.W., Ganz P., et al. Long-term estradiol therapy with or without progesterone improves endothelium-dependent vasodilation in postmenopausal women. Circulation 94 (1996) I-279
47. Glueck C.J., Ping W., Fontaine R.N., Trent T., Sieve-Smith L., and Lang J.E. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the Factor V Leiden mutation (resistance to activated protein C). Am J Cardiol 84 (1999) 549-554
48. Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., and Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68 (1981) 1370-1373
49. Han X., Fiehler R., and Broze Jr. G.J. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci 95 (1998) 9250-9255
50. Han X., Huang Z.F., Fiehler R., and Broze Jr. G.J. The protein Z-dependent protease inhibitor is a serpin. Biochemistry 38 (1999) 11073-11078
51. Han X., Fiehler R., and Broze Jr. G.J. Characterization of the protein Z-dependent protease inhibitor. Blood 96 (2000) 3049-3055
52. Harman S.M., Brinton E.A., Cedars M., Lobo R., Manson J.E., Merriam G.R., et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 8 (2005) 3-12
53. Hasstedt S.J., Bovill E.G., Callas P.W., and Long G.L. An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. Am J Hum Genet 63 (1998) 569-576
54. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet 360 (2002) 7-22
55. Henry M., Aubert H., Morange P.E., Nanni I., Alessi M.C., Tiret L., et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97 (2001) 2053-2058
56. Herrington D.M., and Klein K.P. Genome and hormones: gender differences in physiology invited review: pharmacogenetics of estrogen replacement therapy. J Appl Physiol 91 (2001) 2776-2784
57. Herrington D.M., Fong J., Sempos C.T., Black D.M., Schrott H.G., Rautaharju P., et al. Comparison of the heart and estrogen/progestin replacement study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). Am Heart J 136 (1998) 115-124
58. Herrington D.M., Vittinghoff E., Howard T.D., Major D.A., Owen J., Reboussin D.M., et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 22 (2002) 1012-1017
59. Herzberg M.C., and Meyer M.W. Effects of oral flora on platelets: possible consequences in cardiovascular disease. J Periodontol 67 (1996) 1138-1142 (Suppl.)
60. Hodis H.N., Mack W.J., Lobo R.A., Shoupe D., Sevanian A., Mahrer P.R., et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135 (2001) 939-953
61. Hodis H.N., Mack W.J., Azen S.P., Lobo R.A., Shoupe D., Mahrer P.R., et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. New Engl J Med 349 (2003) 535-545
62. Houston D.S., Shepherd J.T., and Vanhoutte P.M. Adenine nucleotides, serotonin, and endothelium-dependent relaxations to platelets. Am J Physiol 248 (1985) H389-H395
63. Houston D.S., Shepherd J.T., and Vanhoutte P.M. Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries. J Clin Invest 78 (1986) 539-544
64. Hutchinson W.L., Koenig W., Frohlich M., Sund M., Lowe G.D.O., and Pepys M.B. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 46 (2000) 934-938
65. Jayachandran M., and Miller V.M. Molecular and cellular mechanisms of estrogen's actions. In: Douglas P.S. (Ed). Cardiovascular Health and Disease in Women Chapter (2002), Harcourt Health Sciences, Philadelphia, PA 207-230
66. Jayachandran M., and Miller V.M. Human platelets contain estrogen receptor a, caveolin-1 and estrogen receptor associated proteins. Platelets 14 (2003) 75-81
67. Jayachandran M., Owen W.G., and Miller V.M. Effects of ovariectomy on aggregation, secretion, and metalloproteinases in porcine platelets. Am J Physiol: Heart Circ Physiol 284 (2003) H1679-H1685
68. Jayachandran M., Mukherjee R., Steinkamp T., LaBreche P., Bracamonte M.P., Okano H., et al. Differential effects of 17b-estradiol, conjugated equine estrogen and raloxifene on mRNA expression, aggregation and secretion in platelets. Am J Physiol: Heart Circ Physiol 288 (2005) H2355-H2362
69. Jayachandran M., Sanzo A., Owen W.G., and Miller V.M. Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets. Am J Physiol: Heart Circ Physiol 289 (2005) H1908-H1916
70. Jimenez R., Belcher E., Sriskandan S., Lucas R., McMaster S., Vojnovic I., et al. Role of toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proc Natl Acad Sci 102 (2005) 4637-4642
71. Johnson M., Ramey E., and Ramwell P.W. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol 232 (1977) H381-H385
72. Jones C.B., Sane D.C., and Herrington D.M. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 59 (2003) 812-823
73. Juul K., Tybjaerg-Hansen A., Schnnohr P., and Nordestgaard B.G. Factor V Leiden and the risk of venous thromboembolism in the adult Danish population. Ann Intern Med 116 (2004) 851-854
74. Kamada M., Irahara M., Maegawa M., Yasui T., Takeji T., Yamada M., et al. Effect of hormone replacement therapy on post-menopausal changes of lymphocytes and T-cell subsets. J Endocrinol Invest 23 (2000) 376-382
75. Kamikura Y., Wada H., Nobori T., Kobayashi T., Sase T., Nishikawa M., et al. Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thromb Res 116 (2005) 307-312
76. Kannel W.B., Hjortland M.C., McNamara P.M., and Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Int Med 85 (1976) 447-452
77. Karas R.H., Schulten H., Pare G., Aronovitz M.J., Ohlsson C., Gustafsson J.A., et al. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res 89 (2001) 534-539
78. Karnicki K., Owen W.G., Miller R.S., and McBane II R.D. Factors contributing to individual propensity for arterial thrombosis. Arterioscler Thromb Vasc Biol 22 (2002) 1495-1499
79. Khetawat G., Faraday N., Nealen M.L., Vijayan K.V., Bolton E., Noga S.J., et al. Human megakaryocytes and platelets contain the estrogen receptor b and androgen receptor (AR): testosterone regulates AR expression. Blood 95 (2000) 2289-2296
80. Klinger M.H., and Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 22 (2002) 913-922
81. Koeleman B., Reitsma P., Allaart C., and Bertina R. Activated protein C as an additional risk factor for thrombosis in protein C-deficient families. Blood 84 (1994) 1031-1035
82. Koenig W., Sund M., Frohlich M., Fischer H.-G., Lowel H., and Doring A. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
83. Komori K., Shimokawa H., and Vanhoutte P.M. Endothelium-dependent relaxation in response to aggregating platelets in porcine femoral veins and its modulation by diet. Circulation 80 (1989) 401-409
84. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briet E., and Vandenbroucke J.P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. Thromb Haemost 71 (1994) 719-722
85. Koster T., Blann A.D., Briet E., Vandenbroucke J.P., and Rosendaal F.R. Role of clotting factor VIII in effect of van Willebrand factor on occurrence of deep vein thrombosis. Lancet 345 (1995) 152-155
86. Krasinski K., Spyridopoulos I., Asahara T., van der Zee R., Isner J.M., and Losordo D.W. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 95 (1997) 1768-1772
87. Kunnas T.A., Laippala P., Penttila A., Lehtimaki T., and Karhunen P.J. Association of polymorphism of human [alpha] oestrogen receptor gene with coronary artery disease in men: a necropsy study. Br Med J 321 (2000) 273-274
88. Lacut K., Oger E., Le Gal G., Blouch M.-T., Abgrall J.-F., Kerlan V., et al., the SARAH Investigators. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 90 (2003) 124-131
89. Lewis D.A., Bracamonte M.P., Rud K.S., and Miller V.M. Genome and hormones: gender differences in physiology selected contribution: effects of sex and ovariectomy on responses to platelets in porcine femoral veins. J Appl Physiol 91 (2001) 2823-2830
90. Li J.S., LariviŠre R., and Schiffrin E.L. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 24 (1994) 183-188
91. Liang M., Ekblad E., Gustafsson J.A., and Nilsson B.O. Stimulation of vascular protein synthesis by activation of oestrogen receptor beta. J Endocrinol 171 (2001) 417-423
92. Lieberman E.H., Gerhard M.D., Uehata A., Walsh B.W., Selwyn A.P., Ganz P., et al. Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women. Ann Int Med 121 (1994) 936-941
93. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 88 (2001) 756-762
94. Lu Q., Pallas D.C., Surks H.K., Baur W.E., Mendelsohn M.E., and Karas R.H. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor a. Proc Natl Acad Sci 101 (2004) 17126-17131
95. Luscher T.F. Endothelium-derived vasoactive factors and regulation of vascular tone in human blood vessels. Lung Suppl (1990) 27-34
96. Luscher T.F., Diederich D., Siebenmann R., Lehmann K., Stulz P., von Segesser L., et al. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 319 (1988) 462-467
97. Luyer M.D.P., Khosla S., Owen W.G., and Miller V.M. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 86 (2000) 3629-3634
98. MacCallum P., Meade T., Cooper J., Stirling Y., Howarth D., Ruddock V., et al. Clotting factor VIII and risk of deep-vein thrombosis. Lancet 345 (1995) 804
99. Macy E.M., Hayes T.E., and Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43 (1997) 52-58
100. Margolis K.L., Manson J.E., Greenland P., Rodabough R.J., Bray P.F., and Safford M. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women. Arch Intern Med 156 (2005) 500-508
101. Marinelli I., Sacchi E., Landi G., Taioli E., Duca F., and Mannuci P.M. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 338 (1998) 1793-1797
102. Matsuda K., Ruff A., Morinelli T.A., Mathur R.S., and Halushka P.V. Testosterone increases thromboxane A2 receptor density and responsiveness in rat aortas and platelets. Am J Physiol 267 (1994) H887-H893
103. Mattila K.J., Valtonen V.V., Nieminen M., and Hattunen J.K. Dental infection and the risk of new coronary events: prospective study of patients with documented coronary artery disease. Clin Infect Dis 20 (1995) 588-592
104. McBane R.D.I., Karnicki K., Miller R.S., and Owen W.G. The impact of peripheral arterial disease on circulating platelets. Thromb Res 113 (2004) 137-145
105. McConnell J.P., Branum E.L., Ballman K.V., Lagerstedt S.A., Katzmann J.A., and Jaffe A.S. Gender differences in C-reactive protein concentrations-confirmation with two sensitive methods. Clin Chem Lab Med 40 (2002) 56-59
106. McRedmond J.P., Park S.D., Reilly D.F., Coppinger J.A., Maguire P.B., Shields D.C., et al. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics 3 (2004) 133-144
107. Meijers J.C.M., Tekelenburg W.L.H., Bouma B.N., Bertina R.M., and Rosendaal F.R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342 (2000) 696-701
108. Mendelsohn M.E. Mechanisms of estrogen action in the cardiovascular system. J Steroid Biochem Mol Biol 74 (2000) 337-343
109. Meyers D.G. Myocardial infarction, stroke, and sudden cardiac death may be prevented by influenza vaccination. Curr Atheroscler Rep 5 (2003) 146-149
110. Mikkola T.S., and Clarkson T.B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 53 (2002) 605-619
111. Miletich J., Sherman L., and Broze Jr. G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 317 (1987) 991-996
112. Miller V.M. Selective production of endothelium-derived nitric oxide in canine femoral veins. Am J Physiol 261 (1991) H677-H682
113. Miller V.M., and Vanhoutte P.M. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclo-oxygenase. Am J Physiol 248 (1985) H432-H437
114. Miller V.M., and Vanhoutte P.M. Is nitric oxide the only endothelium-derived relaxing factor in canine femoral veins?. Am J Physiol 257 (1989) H1910-H1916
115. Miller V.M., Lewis D.A., and Barber D.A. Gender differences and endothelium-and platelet-derived factors in the coronary circulation. Clin Exper Pharmacol Physiol 26 (1999) 132-136
116. Miller V.M., Shuster L.T., and Hayes S.N. Controversy of hormone treatment and cardiovascular function: need for strengthened collaborations between preclinical and clinical scientists. Curr Opin Invest Drugs 4 (2003) 1220-1232
117. Murohara T., Kugiyama K., Sugiyama S., Ohgushi M., and Yasue H. Activated human polymorphonuclear leukocytes elicit endothelium-dependent contraction in isolated pig coronary arteries. J Cardiovasc Surg 21 (1993) 760-766
118. Myers D.D., Hawley A.E., Farris D.M., Wrobleski S.K., Thanaporn P., Schaub R.G., et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 38 (2003) 1075-1089
119. Nagata Y., Yoshikawa J., Hashimoto A., Yamamoto M., Payne A.H., and Todokoro K. Proplatelet formation of megakaryocytes is triggered by autocrine-synthesized estradiol. Genes Dev 17 (2003) 2864-2869
120. Nair G.V., and Herrington D.M. The ERA trial: findings and implications for the future. Climacteric 3 (2000) 227-232
121. Nakano Y., Oshima T., Ozono R., Ueda A., Oue Y., Matsuura H., et al. Estrogen replacement suppresses function of thrombin stimulated platelets by inhibiting Ca (2+) influx and raising cyclic adenosine monophosphate. Cardiovasc Res 53 (2002) 634-641
122. Nathan L., Pervin S., Singh R., Rosenfeld M., and Chaudhuri G. Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo. Possible mechanisms for gender differences in atherosclerosis. Circ Res 85 (1999) 377-385
123. Nathan L., Shi W., Dinh H., Mukherjee T.K., Wang X., Lusis A.J., et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A 98 (2001) 3589-3593
124. New G., Timmins K.L., Duffy S.J., Tran B.T., O'Brien R.C., Harper R.W., et al. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 29 (1997) 1437-1444
125. New G., Duffy S.J., Harper R.W., and Meredith I.T. Estrogen improves acetylcholine-induced but not metabolic vasodilation in biological males. Am J Physiol: Heart Circ Physiol 277 (1999) H2341-H2347
126. Nilsson B.O., Ekblad E., Heine T., and Gustafsson J.A. Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor beta knock-out mice. J Endocrinol 166 (2000) R5-R9
127. Nishida M., Kuzuya T., and Hoshida S. Polymorphonuclear leukocytes induced vasoconstriction in isolated canine coronary arteries. Circ Res 66 (1990) 253
128. Ockene I.S., Matthews C.E., Rifai N., Ridker P.M., Reed G., and Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47 (2001) 444-450
129. Ohtaki Y., Shimauchi H., Yokochi T., Takada H., and Endo Y. In vivo platelet response to lipopolysaccharide in mice: proposed method for evaluating new antiplatelet drugs. Thromb Res 108 (2003) 303-309
130. Oparil S., Chen S.J., Chen Y.F., Durand J.N., Allen L., and Thompson J.A. Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries. Cardiovasc Res 44 (1999) 608-614
131. Pare G., Krust A., Karas R.H., Dupont S., Aronovitz M., Chambon P., et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90 (2002) 1087-1092
132. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
133. Perez Gutthann S., Garcia Rodriguez L.A., Castellsague J., and Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Brit Med J 314 (1997) 796-800
134. Poelzl G., Kasai Y., Mochizuki N., Shaul P.W., Brown M., and Mendelsohn M.E. Specific association of estrogen receptor beta with the cell cycle spindle assembly checkpoint protein, MAD2. Proc Natl Acad Sci U S A 97 (2000) 2836-2839
135. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
136. Post W.A., Goldschmidt-Clermont P.J., Wilhide C.C., Heldman A.W., Sussman M.S., Ouyang P., et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 43 (1999) 985-991
137. Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. Prospective analysis from the Women's Health Initiative Observational Study. JAMA 288 (2002) 980-987
138. Prandoni P., Bilora F., Marchiori A., Bernardi E., Petrobelli F., Lensing A.W.A., et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 348 (2003) 1435-1441
139. Price D.T., and Ridker P.M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Int Med 127 (1997) 895-903
140. Radomski M.W., Palmer R.M., and Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 148 (1987) 1482-1489
141. Rauch U., Bonderman D., Bohrmann B., Badimon J.J., Himber J., Riederer M.A., et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 96 (2000) 170-175
142. Razandi M., Pedram A., Merchenthaler I., Greene G.L., and Levin E.R. Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol 18 (2004) 2854-2865
143. Rhodes J.M., Cho J.-S., Gloviczki P., Mozes G., Rolle R., and Miller V.M. Thrombolysis for experimental deep venous thrombosis maintains valvular competence and vasoreactivity. J Vasc Surg 31 (2000) 1193-1205
144. Ridker P.M., Hennekens C.H., Nader R., Buring J.E., and Manson J.E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100 (1999) 713-716
145. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(s), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 (2001) 2481-2485
146. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14 719 initially healthy American women. Circulation 107 (2003) 391-397
147. Ridker P., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
148. Ridker P.M., Cook N.R., Lee I.-M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1-12
149. Rosendaal F.R., and Bovill E.G. Heritability of clotting factors and the revival of the prothrombotic state. Lancet 359 (2002) 638-639
150. Rosendaal F.R., Koster T., Vandebroucke J.P., and Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85 (1995) 1504-1508
151. Rosendaal F.R., Helmerhorst F.M., and Vandenbroucke J.P. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22 (2002) 201-210
152. Rosendaal F.R., Vessey M.P., and Rumley A. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Brit J Haematol 116 (2002) 851-854
153. Ross R., and Glomset J.A. The pathogenesis of atherosclerosis. N Engl J Med 295 (1976) 420-425
154. Rubanyi G.M., Freay A.D., Kauser K., Sukovich D., Burton G., Lubahn D.B., et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and the effect of estrogen receptor gene disruption. J Clin Invest 99 (1997) 2429-2437
155. Sayegh H.S., Ohara Y., Navas J.P., Peterson T.E., Dockery S.P., and Harrison D.G. Endothelial nitric oxide synthase regulation by estrogens. Circulation 88 (1993) I-80
156. Scarabin P.Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., and Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol 17 (1997) 3071-3078
157. Scarabin P.-V., Oger E., and Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. The Lancet 362 (2003) 428-432
158. Seligsohn U., Berger A., Abend M., Rubin L., Attias D., Zivelin A., et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 310 (1984) 559-562
159. Sessa W.C., Kaw S., Hecker M., and Vane J.R. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun 174 (1991) 613-618
160. Sevitt S. Pathology and pathogenesis of deep vein thrombi. In: Bergan J.J., and Yao J.S.T. (Eds). Venous Problems (1978), Year Book Medical Publishers, Chicago, IL 257-279
161. Shaul P.W. Novel role of estrogen receptors in vascular endothelium. Semin Perinatol 24 (2000) 70-74
162. Shearman A.M. Hormone receptor polymorphisms. In: Bittar E.E. (Ed). Principles of Sex-Based Differences in Physiology (2004), Elsevier B.V., Amsterdam, The Netherlands 59-69
163. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Kensuke M., et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4. J Exp Med 189 (1999) 1777-1782
164. Souto J., Almasy L., Borrell M., Blanco-Vaca F., Mateo J., Soria J., et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet 67 (2000) 1452-1459
165. Souto J., Almasy L., Borrell M., Gari M., Martinez E., Mateo J., et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 101 (2000) 1546-1551
166. Steudel W., Ichinose F., Huang P.L., Hurford W.E., Jones R.C., Bevan J.A., et al. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res 81 (1997) 34-41
167. Sudhir K., Chou T.M., Chatterjee K., Smith E.P., Williams T.C., Kane J.P., et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96 (1997) 3774-3777
168. Sullivan Jr. T.R., Karas R.H., Aronovitz M., Faller G.T., Ziar J.P., Smith J.J., et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 96 (1995) 2482-2488
169. Szalai A.J., and McCrory M.A. Varied biologic functions of C-reactive protein. Lessons learned from transgenic mice. Immunol Res 3 (2002) 279-287
170. Tanus-Santos J.E., Desai M., Deak L.R., Pezzullo J.C., Abernethy D.R., Flockhart D.A., et al. Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 12 (2002) 407-413
171. Taylor F.B. Response of anticoagulant pathways in disseminated intravascular coagulation. Semin Thromb Hemost 27 (2001) xiv619-xiv632
172. The Women's Health Initiative Study Group. Design of the women's health initiative clinical trial and observational study. Controlled Clin Trials 19 (1998) 61-109
173. Tracy R.P., Psaty B.M., Macy E., Bovill E.G., Cushman M., Cornell E.S., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in elderly subjects. Arterioscler Thromb Vasc Biol 17 (1997) 2167-2176
174. van Boven H.A., Reitsma P.H., Rosendaal F.R., Bayston T.A., Chowdhury V., Bauer K.A., et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 75 (1996) 417-421
175. van der Logt C.P.E., Dirven R.J., Reitsma P.H., and Bertina R.M. Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester. Blood Coagulation Fibrinolysis 5 (1994) 211-220
176. van Hylckama Vlieg A., van der Linden I.K., Bertina R.M., and Rosendaal F.R. High levels of factor IX increase the risk of venous thrombosis. Blood 95 (2000) 3678-3682
177. van Kesteren P.J., Asscheman H., Megens J.A., and Gooren L.J. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol 47 (1997) 337-342
178. van Tilberg N.H., Rosendaal F.R., and Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
179. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., and Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344 (1994) 1453-1457
180. Varas-Lorenzo C., Garcia-Rodriguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L., and Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 147 (1998) 387-390
181. Varas-Lorenzo C., Garcia-Rodriguez L.A., Perez-Gutthann S., and Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation 101 (2000) 2572-2578
182. Viles-Gonzalez J.F., Fuster V., and Badimon J.J. Thrombin/inflammation paradigms: a closer look at arterial and venous thrombosis. Am Heart J 149 (2005) S19-S31
183. Virchow R.L.K. Phlogose und thrombose in gefabsystem. Gesammelte Abhandlungen zur wisenshcaftlichen Medicin (1856), Verlag Von Meidinger Sohn and Comp, Frankfurt A.M. 458-633
184. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 38 (2001) 189-197
185. Vongpatanasin W., Tuncel M., Wang Z., Arbique D., Mehrad B., and Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 41 (2003) 1358-1363
186. Walsh B.W., Paul S., Wild R.A., Dean R.A., Tracy R.P., Cox D.A., et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85 (2000) 214-218
187. Walsh B., Cox D.A., Sashegyi A., Dean R.A., Tracy R.P., and Anderson P.W. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 88 (2001) 825-828
188. White C.R., Shelton J., Chen S.-J., Darley-Usmar V., Allen L., Nabors C., et al. Estrogen restores endothelial cell function in an experimental model of vascular injury. Circulation 96 (1998) 1624-1630
189. Wilkins J., Gallimore J.R., Moore E.G., and Pepys M.B. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 44 (1998) 1358-1361
190. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
191. Yang Z., Stultz P., von-Segesser L., Bauer E., Turina M., and Luscher T.F. Different interactions of platelets with arterial and venous coronary bypass vessels. Lancet 337 (1991) 939-943
192. Yin Z.F., Huang Z.F., Cui J., Fiehler R., Lasky N., Ginsburg D., et al. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci 97 (2000) 6734-6738
193. Young B., Gleeson M., and Cripps A.W. C-reactive protein: a critical review. Pathology 23 (1991) 118-124
194. Zhu Y., Bian Z., Lu P., Karas R.H., Bao L., Cox D., et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 295 (2002) 505-508
195. Zoldhelyi P., Chesebro J.H., and Owen W.G. Hirudin as a molecular probe for thrombin in vitro and during systemic coagulation in the pig. Proc Natl Acad Sci U S A 90 (1993) 1819-1823
196. Zoller B., Berntsdotter A., Carcia de Frutos P., and Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 85 (1995) 3518-3523